Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study

Journal of Critical Care

Volumn 43, Issue , 2018, Pages 183-189

  Pereira, J M ^a,b,c   Goncalves Pereira J ^d,g   Ribeiro, O ^b   Baptista, J P ^e   Froes, F ^f   Paiva, J A ^a,b,c  

^a Universidade do Porto   (Portugal)

^b University of Porto   (Portugal)

^c Grupo Infeção e Sepsis   (Portugal)

^d Vila Franca de Xira Hospital and Internal Medicine Department of the CUF Torres Vedras Hospital   (Portugal)

^e CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^f HOSPITAL PULIDO VALENTE   (Portugal)

^g NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

Antibiotic therapy; Critically ill; Mortality; Outcome; Severe community acquired pneumonia

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; MACROLIDE; ANTIINFECTIVE AGENT; BETA LACTAM; LACTIC ACID;

ACINETOBACTER; ADULT; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; INAPPROPRIATE PRESCRIBING; INFLUENZA A VIRUS (H1N1); INTENSIVE CARE UNIT; KLEBSIELLA; LEGIONELLA PNEUMOPHILA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORAXELLA CATARRHALIS; MORTALITY; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PROSPECTIVE STUDY; PROTEUS; PSEUDOMONAS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SERRATIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BACTERIAL PNEUMONIA; BLOOD; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED INFECTION; CRITICAL ILLNESS; HOSPITAL MORTALITY; ORGAN DYSFUNCTION SCORE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITAL MORTALITY; HUMANS; LACTIC ACID; LENGTH OF STAY; LOGISTIC MODELS; MACROLIDES; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PNEUMONIA, BACTERIAL; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 85037702586     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2017.08.048     Document Type: Article

References (33)

1. Osler, W., The principles and practice of medicine. Designed for the use of practitioners and students of medicine. 1892, D. Appleton and Company, New York.
2. Fine, M.J., SM, Carson, C.A., Mutha, S.S., Sankey, S.S., Weissfeld, L.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 275:2 (1996), 134–141.
3. Bauer, T.T., WT, Ernen, C., Schlosser, B.M., Thate-Waschke, I., de Zeeuw, J., et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 128:4 (2005), 2238–2246.
4. Colice, G.L., MM, Asche, C., Birnbaum, H.G., Treatment Costs of Community-acquired Pneumonia in an Employed Population. 125, 2004, 2140–2145 (6).
5. Chalmers, J.D., MP, Singanayagam, A., Akram, A.R., Choudhury, G., Short, P.M., et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 37:9 (2011), 1409–1420.
6. Brito, V., NM, How Does One Diagnose and Manage Severe Community-acquired Pneumonia? Evidence-based Practice of Critical Care. 2011, 253–262.
7. Mandell, L.A., WR, Anzueto, A., Infectious Disease Society of American/American Thoracic Society consensus guidelines for the management of community acquired pneumonia in adults. Clin Infect Dis 44 (2007), S27–72.
8. Woodhead, M., BF, Ewig, S., Garau, J., Huchon, G., Ieven, M., et al. Guidelines for the management of adult lower respiratory tract infections- full version. Clin Microbiol Infect 17:Suppl6 (2011), E1–59.
9. Lim, W.S., BS, George, R.C., Hill, A.T., Jamieson, C., Le Jeune, I., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64:Suppl. 3 (2009), iii1–55.
10. Baddour, L.M., YV, Klugman, K.P., Feldman, C., Ortqvist, A., Rello, J., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:4 (2004), 440–444.
11. Waterer, G.W., SG, Wunderink, R.G., Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161 (2001), 1837–1842.
12. Martínez, J.A., HJ, Almela, M., Marco, F., Soriano, A., García, E., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:4 (2003), 389–395.
13. Rodríguez, A., MA, Sirvent, J.M., Barcenilla, F., de la Torre-Prados, M.V., Solé-Violán, J., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35:6 (2007), 1493–1498.
14. Martin-Loeches, I., LT, Rodriguez, A., Putensen, C., Annane, D., Garnacho-Montero, J., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36:4 (2010), 612–620.
15. Mufson, M.A., SR, Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med 107:1A (1999), 34S–43S.
16. Weiss, K., LD, Cortes, L., Beaupre, A., Gauthier, R., Gregoire, P., et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 11:8 (2004), 589–593.
17. Gonçalves-Pereira, J., PJ, Ribeiro, O., Baptista, J.P., Froes, F., Paiva, J.A., Impact of infection on admission and of the process of care on mortality of patients admitted to the Intensive Care Unit: the INFAUCI study. Clin Microbiol Infect 20:12 (2014), 1308–1315.
18. Levy, M.M., FM, Marshall, J.C., SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003:31 (2003), 1250–1256.
19. File, T.M. Jr., MT, Burden of community-acquired pneumonia in north American adults. Postgrad Med 122 (2010), 130–141.
20. Gattarello, S., BB, Solé-Violán, J., Vallés, J., Vidaur, L., Zaragoza, R., et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013). Chest 146:1 (2014), 22–31.
21. Gattarello, S., LL, Vidaur, L., Solé-Violán, J., Zaragoza, R., Vallés, J., et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. Crit Care, 2015, 19.
22. Postma, D.F., VWC, van Elden, L.J., Thijsen, S.F., Hoepelman, A.I., Kluytmans, J.A., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372:14 (2015), 1312–1323.
23. Adrie, C., SC, Garrouste-Orgeas, M., Vignoud, L., Planquette, B., Azoulay, E., et al. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Crit Care, 17, 2013.
24. Sligl, W.I., AL, Eurich, D.T., Tjosvold, L., Marrie, T.J., Majumdar, S.R., Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 42:2 (2014), 420–432.
25. Aspa, J., RO, Rodriguez de Castro, F., Huertas, M.C., Borderías, L., Cabello, F.J., et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27:5 (2006), 1010–1019.
26. Kumar, A., ZR, Light, B., Parrillo, J., Maki, D., Simon, D., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 38:9 (2010), 1773–1785.
27. Garnacho-Montero, J., G.-G.J, Barrero-Almodovar, A., Jimenez-Jimenez, F.J., Perez-Paredes, C., Ortiz-Leyba, C., Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:12 (2003), 2742–2751.
28. Kumar, A., EP, Arabi, Y., Roberts, D., Light, B., Parrillo, J.E., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:5 (2009), 1237–1248.
29. Falagas, M.E., SI, Bliziotis, I.A., Panos, G.Z., Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc 81:12 (2006), 1567–1574.
30. Uranga, A., EP, Bilbao, A., Quintana, J.M., Arriaga, I., Intxausti, M., et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 176:9 (2016), 1257–1265.
31. Choudhury, G., MP, Singanayagam, A., Akram, A.R., Chalmers, J.D., Hill, A.T., Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia - a propensity-adjusted analysis. Clin Microbiol Infect 17:12 (2011), 1852–1858.
32. Mikkelsen, M.E., MA, Gaieski, D.F., Goyal, M., Fuchs, B.D., Shah, C.V., et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 37:5 (2009), 1670–1677.
33. Gwak, M.H., JS, Jeong, T., Lee, J.B., Jin, Y.H., Yoon, J., et al. Initial serum lactate level is associated with inpatient mortality in patients with community-acquired pneumonia. Am J Emerg Med 33:5 (2015), 685–690.